IAPSM's Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India.

IF 0.9 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Indian Journal of Community Medicine Pub Date : 2024-12-01 Epub Date: 2024-12-30 DOI:10.4103/ijcm.ijcm_739_24
Chythra R Rao, Veena G Kamath, Anuradha Nadda, Swayam P Parida, Nikita Sharma, Kapil Goel, Ranjitha S Shetty, Madhur Verma, Arvind Kumar Singh, Abhisek Mishra, Swosti Kiran, Lalit Sankhe, Madhu Gupta
{"title":"IAPSM's Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India.","authors":"Chythra R Rao, Veena G Kamath, Anuradha Nadda, Swayam P Parida, Nikita Sharma, Kapil Goel, Ranjitha S Shetty, Madhur Verma, Arvind Kumar Singh, Abhisek Mishra, Swosti Kiran, Lalit Sankhe, Madhu Gupta","doi":"10.4103/ijcm.ijcm_739_24","DOIUrl":null,"url":null,"abstract":"<p><p>Pneumococcal infection among adults is associated with invasive disease and poor outcomes. Pneumococcal vaccine (PCV) introduction has significantly reduced disease burden, invasive disease and reduced the rates of antimicrobial resistance. Of the various vaccines licensed, PCV 13 and PPSV 23 are available for use in India. Pneumococcal vaccination is suggested for people aged 19-64 years with immunosuppression, chronic cardiac, lung and hepatic disease, impaired splenic function, uncontrolled diabetes mellitus, current smokers, and those abusing alcohol. It is recommended that people >65 years of age are vaccinated with PPSV23. The suggested regimen is to administer PCV13 followed by PPSV23 after one year. The vaccines have minimal side effects and tolerated well. Data on vaccine effectiveness from Indian studies is limited. Hence, documenting population demographics with surveillance on serotype specific pneumococcal disease burden in adults is needed. Following this, studies on safety, immunogenicity, and cost-effectiveness of the available vaccines need to be designed and implemented. It is suggested that in the initial phase, PCV needs to be made available for high-risk population followed by vaccination roll-out for adult population of India.</p>","PeriodicalId":45040,"journal":{"name":"Indian Journal of Community Medicine","volume":"49 Suppl 2","pages":"S132-S138"},"PeriodicalIF":0.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927817/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Community Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijcm.ijcm_739_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Pneumococcal infection among adults is associated with invasive disease and poor outcomes. Pneumococcal vaccine (PCV) introduction has significantly reduced disease burden, invasive disease and reduced the rates of antimicrobial resistance. Of the various vaccines licensed, PCV 13 and PPSV 23 are available for use in India. Pneumococcal vaccination is suggested for people aged 19-64 years with immunosuppression, chronic cardiac, lung and hepatic disease, impaired splenic function, uncontrolled diabetes mellitus, current smokers, and those abusing alcohol. It is recommended that people >65 years of age are vaccinated with PPSV23. The suggested regimen is to administer PCV13 followed by PPSV23 after one year. The vaccines have minimal side effects and tolerated well. Data on vaccine effectiveness from Indian studies is limited. Hence, documenting population demographics with surveillance on serotype specific pneumococcal disease burden in adults is needed. Following this, studies on safety, immunogenicity, and cost-effectiveness of the available vaccines need to be designed and implemented. It is suggested that in the initial phase, PCV needs to be made available for high-risk population followed by vaccination roll-out for adult population of India.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Indian Journal of Community Medicine
Indian Journal of Community Medicine PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
1.30
自引率
0.00%
发文量
85
审稿时长
49 weeks
期刊介绍: The Indian Journal of Community Medicine (IJCM, ISSN 0970-0218), is the official organ & the only official journal of the Indian Association of Preventive and Social Medicine (IAPSM). It is a peer-reviewed journal which is published Quarterly. The journal publishes original research articles, focusing on family health care, epidemiology, biostatistics, public health administration, health care delivery, national health problems, medical anthropology and social medicine, invited annotations and comments, invited papers on recent advances, clinical and epidemiological diagnosis and management; editorial correspondence and book reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信